INTRODUCTION: The aim of the study was to determine the level of metabolic control in type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) patients in the Czech and Slovak Republics. METHODS: A non-interventional prospective (observational) study was conducted from January 2015 until April 2016 in routine clinical practice settings at 141 centers in the Czech and Slovak Republics. Data were analyzed from a total of 425 patients with T1DM and 1034 patients with T2DM, proportionally corresponding to the number of patients in both countries. The primary objective of the study was to determine the percentage of patients with HbA1c < 7% (53 mmol/mol). RESULTS: Patients with T1DM: In this group of patients (55.8% males, mean age 45.9 ± 14.83 years, BMI 25.8 ± 4.21 kg/m², diabetes duration 12.1 ± 9.44 years), 29.9% reached HbA1c levels < 53 mmol/mol. Patients with T2DM: In this group of patients (50.3% male, mean age 63.9 ± 9.65 years, BMI 31.0 ± 5.19 kg/m², diabetes duration 12.4 ± 7.47 years, duration of insulin therapy 5.8 ± 4.71 years), 33.4% reached HbA1c levels < 53 mmol/mol. CONCLUSION: The overall percentage of patients with HbA1c < 53 mmol/mol in the T1DM group was 29.9% and in the T2DM group was 33.4%. Despite an increasing number of treatment options, most patients still fail to reach the recommended HbA1c targets. FUNDING: Sanofi, Czech Republic.

Aprova sro Brno Czech Republic

Center for Research in Diabetes Metabolism and Nutrition 2nd Department of Internal Medicine 3rd Faculty of Medicine Charles University Prague Czech Republic

Czech Institute of Informatics Robotics and Cybernetics Czech Technical in University Prague Czech Republic

Department of Internal Medicine 2nd Faculty of Medicine Charles University Prague Prague Czech Republic

Institute of Computer Science of the ASCR v v i Prague Czech Republic

National Institute of Endocrinology and Diabetology Lubochna Slovakia

Private Department of Diabetology Internal Medicine and Metabolism Kosice Slovakia

Zobrazit více v PubMed

DCCT Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986. doi: 10.1056/NEJM199309303291401. PubMed DOI

Nathan DM. DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37(1):9–16. doi: 10.2337/dc13-2112. PubMed DOI PMC

Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes UK prospective diabetes study (UKPDS 35): prospective observational study. Br Med J. 2000;321:405–412. doi: 10.1136/bmj.321.7258.405. PubMed DOI PMC

Vanstone M, Rewegan A, Brundisini F, Dejean D, Giacomini M. Patient perspectives on quality of life with uncontrolled type 1 diabetes mellitus: a systematic review and qualitative meta-synthesis. Ont Health Technol Assess Ser. 2015;15(17):1–29. PubMed PMC

da Mata AR, Álvares J, Diniz LM, et al. Quality of life of patients with Diabetes Mellitus Types 1 and 2 from a referal health centre in Minas Gerais, Brazil. Expert Rev Clin Pharmacol. 2016;9(5):739–746. doi: 10.1586/17512433.2016.1152180. PubMed DOI

Kuznetsov L, Griffin SJ, Davies MJ. Diabetes-specific quality of life but not health status is independently associated with glycaemic control among patients with type 2 diabetes: a cross-sectional analysis of the addition-Europe trial cohort. Diabetes Res Clin Pract. 2014;104:281–287. doi: 10.1016/j.diabres.2013.12.029. PubMed DOI

American Diabetes Association Glycemic targets. Sec. 6. In standards of medical care in diabetes 2017. Diabetes Care. 2017;40(Suppl. 1):S48–S56. doi: 10.2337/dc17-S009. PubMed DOI PMC

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American diabetes association (ADA) and the European association for the study of diabetes (EASD) Diabetes Care. 2015;38(1):140–149. doi: 10.2337/dc14-2441. PubMed DOI

Pablos-Velasco P, Parhofer KG, Bradley C, Eschwege E, Gonder-Frederick L, Maheux P, et al. Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clin Endocrinol. 2014;80:47–56. doi: 10.1111/cen.12119. PubMed DOI

Andel M, Grzeszczak W, Michalek J, Medvescek M, Norkus A, Rasa I, et al. A multinational, multi-centre, observational, cross-sectional survey assessing diabetes secondary care in central and Eastern Europe (DEPAC survey) Diabet Med. 2008;25(10):1195–1203. doi: 10.1111/j.1464-5491.2008.02570.x. PubMed DOI

Selvin E, Parrinello ChM, Daya N, Bergenstal RM. Trends in insulin use and diabetes control in the US: 1988–1994 and 1999–2012. Diabetes Care. 2016;39(3):e33–e35. doi: 10.2337/dc15-2229. PubMed DOI PMC

Brož J, Janíčková Žďárská D, Urbanová J, Brabec M, Křivská B, Doničová V, et al. An international, multicenter, observational survey to evaluate diabetes control in subjects using insulin for the treatment of type 1 and type 2 diabetes mellitus in the Czech Republic and Slovakia: study protocol for a cross-sectional survey. Open Access J Clin Trials. 2016 doi: 10.2147/OAJCT.S103459. DOI

Riddle MC, Bolli GB, Ziemen M, Muehlen-Bartmer I, Bizet F, Home PD. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1) Diabetes Care. 2014;37(10):2755–2762. doi: 10.2337/dc14-0991. PubMed DOI

Rosenstock J, Hollander P, Bhargava A, Ilag LL, Pollom RK, Zielonka JS, et al. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study) Diabetes Obes Metab. 2015;17(8):734–741. doi: 10.1111/dom.12482. PubMed DOI

Riebenfeld D, Spirk D, Mathis A, Villiger L, Gerber PA, Gasser UE, Lehmann R. Treatment intensification with insulin glargine in patients with inadequately controlled type 2 diabetes improves glycaemic control with a high treatment satisfaction and no weight gain. Swiss Med Wkly. 2015;145:w14114. doi: 10.4414/smw.2015.14114. PubMed DOI

Reach G, Pechtner V, Gentilella R, Corcos A, Ceriello A. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab. 2017;43(6):501–511. doi: 10.1016/j.diabet.2017.06.003. PubMed DOI

Fisher SJ, Huang X, Pawaskar M, et al. Hypoglycemia in type 2 diabetes: understanding patients’ and physicians’ knowledge and experience. Endocrine. 2018;60:435–444. doi: 10.1007/s12020-018-1545-0. PubMed DOI

Methodological Considerations for a Diabetes Family-Based eHealth Intervention

Dynamics of glucose concentration during the initiation of ketogenic diet treatment in children with refractory epilepsy: Results of continuous glucose monitoring

New Frontiers in Diabetes Care

A Telemedicine System Intervention for Patients With Type 1 Diabetes: Pilot Feasibility Crossover Intervention Study

Dysglycemia and Abnormal Adiposity Drivers of Cardiometabolic-Based Chronic Disease in the Czech Population: Biological, Behavioral, and Cultural/Social Determinants of Health

Insulin Management of Patients with Inadequately Controlled Type 2 Diabetes Admitted to Hospital: Titration Patterns and Frequency of Hypoglycemia as Results of a Prospective Observational Study (Hospital Study)

Results of Insulin Therapy in Type 2 Diabetes Mellitus Patients in the Czech Republic: Do They Reflect the Current Status in Other Countries?

Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi

Addition of Basal Insulin to Oral Antidiabetic Agents in Patients with Inadequately Controlled Type 2 Diabetes Leads to Improved HbA1c Levels: Metabolic Control, Frequency of Hypoglycemia, and Insulin Titration Analysis as Results of a Prospective Observational Study (BALI Study)